Head-To-Head Analysis: Lexaria Bioscience (LEXX) & The Competition

Lexaria Bioscience (NASDAQ:LEXX) is one of 897 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Lexaria Bioscience to similar companies based on the strength of its risk, valuation, earnings, institutional ownership, profitability, analyst recommendations and dividends.

Earnings & Valuation

This table compares Lexaria Bioscience and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lexaria Bioscience	$194,000.00	-$11.90 million	-0.68
Lexaria Bioscience Competitors	$4.62 billion	$3.22 billion	545.49

Lexaria Bioscience’s competitors have higher revenue and earnings than Lexaria Bioscience. Lexaria Bioscience is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

13.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 32.4% of shares of all “Pharmaceuticals” companies are held by institutional investors. 8.4% of Lexaria Bioscience shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility and Risk

Lexaria Bioscience has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Lexaria Bioscience’s competitors have a beta of -4.29, suggesting that their average share price is 529% less volatile than the S&P 500.

Profitability

This table compares Lexaria Bioscience and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-174.93%	-143.89%
Lexaria Bioscience Competitors	-2,380.91%	-221.73%	-15.99%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Lexaria Bioscience and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1	0	1	0	2.00
Lexaria Bioscience Competitors	7764	13847	25695	1031	2.41

Lexaria Bioscience presently has a consensus price target of $22.50, indicating a potential upside of 544.70%. As a group, “Pharmaceuticals” companies have a potential upside of 23.91%. Given Lexaria Bioscience’s higher probable upside, equities research analysts clearly believe Lexaria Bioscience is more favorable than its competitors.

Summary

Lexaria Bioscience competitors beat Lexaria Bioscience on 9 of the 13 factors compared.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.